COA and Lot Traceability: The Backbone of Reproducible Pharma Research
Vini, Contractual Content Partner, Compound Vitality
Experimental results in pharmaceutical research depend not only on method and equipment but also on the reagents used. Because research materials are manufactured in lots, one lot cannot be assumed to match the next. This article explains how lot-specific Certificates of Analysis and lot traceability link results to the exact material tested, narrow the investigation of unexpected shifts, and support reproducibility. It also outlines the minimum lot records laboratories should keep and notes their alignment with data integrity expectations.
A pharmaceutical experiment can be repeated with the same protocol, instrument settings, and analyst, yet still produce a different result. The obvious suspects are usually the method or the equipment. Sometimes the less visible variable is the material itself.
Research compounds, standards, proteins, antibodies, and other reagents are manufactured in lots. Even when the product name and nominal specification remain unchanged, one lot is not automatically interchangeable with the next. That makes two pieces of documentation especially important: the Certificate of Analysis (COA) and the lot number. Together, they connect an experimental result to the actual material used to generate it.
Reproducibility starts before the assay
Reproducibility is often discussed as a question of protocol design, instrument performance and statistical analysis. Those factors matter, but they sit downstream of material identity and quality.
If a laboratory cannot establish which lot of a critical reagent was used, it loses an important part of the experimental record. A later repeat may follow the same written method but use a different production lot with slightly different purity, activity, impurity profile or handling history. The method appears unchanged while one of its inputs has changed.
Recent laboratory quality research continues to treat lot-to-lot reagent variation as a source of analytical error that should be assessed before a new lot enters routine use[1]. The principle translates beyond clinical testing. Where a reagent materially influences an assay, its lot belongs in the record.
A COA should describe the material actually used
A COA is useful only when it can be tied to a specific batch. A generic specification sheet may describe what a product is intended to meet, but it does not show what was measured for the material sitting on the laboratory bench.
For research compounds, a lot-specific Certificate of Analysis can provide the link between the labelled vial and analytical evidence such as the compound identity, batch identifier, test date, purity result and analytical method[2]. Depending on the material and intended research use, additional attributes may also matter, including water content, residual solvents, counterion content, endotoxin or sterility testing.
The important point is not the number of fields on the certificate. It is whether the document answers a simple question: does this analytical record belong to this exact lot?
A COA should also be read for what it does not establish. For example, a purity result alone does not demonstrate potency, sterility, stability or suitability for a particular assay. Likewise, documentation supplied with a research-use material does not convert that material into GMP or clinical-grade product. The analytical claim and the intended use have to remain separate.
Traceability turns unexpected results into testable questions
The practical value of lot traceability becomes clearest when something changes.
Consider an assay that has performed consistently for months and then begins to shift after fresh reagent stock is introduced. Without lot records, the investigation may start with the instrument, analyst, software, calibration and sample preparation. All are reasonable possibilities, but the laboratory may have no easy way to test whether the reagent changed.
With lot-level records, the investigation becomes narrower. The laboratory can identify the date the new lot entered use, compare results before and after the change, review the corresponding COA, examine storage history and, where appropriate, run a bridging or comparability assessment.
This is especially relevant to long-running pharmaceutical studies. A recent bioanalysis white paper notes that assay performance can drift over time because of factors including lot-to-lot variability in critical reagents, and recommends approaches such as trending and bridging to monitor consistency[3]. The message is straightforward: a lot change should be treated as an experimental event, not an administrative detail.
Analytical results need context
Chromatography and mass spectrometry are powerful tools, but the value of their results depends on how well those results remain connected to the sample tested.
For a peptide or similar research compound, an HPLC result may provide evidence about purity, while mass spectrometry can support identity by confirming the expected molecular mass. Those findings become far more useful when the COA also identifies the lot, method, testing date and responsible laboratory.
This context matters during comparison. Two COAs reporting similar headline purity values may still differ in analytical conditions, acceptance criteria or the attributes tested. A laboratory therefore gains little from recording only a percentage in a notebook. The underlying document, lot identifier and relevant method information should remain retrievable.
Good traceability also protects against a surprisingly common problem: retrospective uncertainty. Months after an experiment, a result may attract renewed attention because another team cannot reproduce it or because a development programme has moved forward. At that point, "same reagent" is not enough. The useful question is "same reagent, same lot, supported by the same analytical documentation?"
Digital records make lot history usable
Lot traceability works best when it is built into routine laboratory documentation rather than reconstructed during an investigation. Laboratory notebooks, electronic lab notebooks and LIMS can capture lot numbers at the point of use and link them with COAs or supplier records.
The record does not need to become cumbersome. For materials that can materially affect an experiment, the useful minimum normally includes the product or material name, supplier, lot or batch identifier, date received or opened where relevant, storage conditions, expiry or retest date, and a retrievable COA.
That information creates a chain from material receipt to experiment and, later, to investigation. It also supports better change control when suppliers, lots or analytical specifications change.
Regulators place similar emphasis on trustworthy records at a broader level. In its 2026 data integrity updates, the FDA reiterated sponsor responsibility for the integrity and reliability of study data[4]. Lot traceability is only one part of that wider discipline, but it follows the same logic: conclusions are stronger when the underlying evidence can be reconstructed.
The certificate is not the endpoint
COAs and lot numbers can look like procurement paperwork. In a reproducible research system, they are part of the experimental method.
A strong COA establishes what was tested for a defined lot. Traceability records where and when that lot was used. Together, they allow researchers to distinguish a genuine scientific effect from a material change that might otherwise remain invisible.
The goal is not more documentation for its own sake. It is to preserve enough context that a result can be examined, challenged and repeated. When that context is missing, reproducibility becomes a matter of luck, partly. When it is preserved, the laboratory has something far more useful: an evidence trail.
References
[1] Badrick T, Fortun M, Vayanos Z, Bernard M, Dufour P, Souied L, Giannoli J-M. Quality control for serological testing. Clin Chim Acta. 2025;564:119905. doi:10.1016/j.cca.2024.119905. https://www.sciencedirect.com/science/article/abs/pii/S0009898124021582
[2] Compound Vitality. COA / Lab Results: Certificates of Analysis [Internet]. Compound Vitality; 2026 [cited 2026 Oct 1]. https://compoundvitality.com/coa-lab-results/
[3] Hersey S, McGuire K, Kholmanskikh O, et al. 2025 White Paper on Recent Issues in Bioanalysis: Biomarkers Calibrators & Stability; Evaluation of NULISA; Neurofilament & Autoantibody Biomarker Assays; Removing IgM Interference; ELISpot & FluoroSpot Best Practices; Modular HD Cytometry; Single-cell Analysis Imaging Cytometry (Part 2A and Part 2B). Bioanalysis. 2025;17(23):1481-1533. doi:10.1080/17576180.2025.2599698. https://www.tandfonline.com/doi/full/10.1080/17576180.2025.2599698
[4] U.S. Food and Drug Administration. Notifications on Data Integrity [Internet]. FDA; content current as of 2026 Jul 14 [cited 2026 Oct 1]. https://www.fda.gov/drugs/drug-safety-and-availability/notifications-data-integrity
Vini holds an M.S. in Biochemistry and works as a contractual content partner with Compound Vitality. With a strong foundation in biological sciences and research principles, she helps develop clear, research-focused educational content around peptides and related scientific topics.
